[1] 刘玉萍, 刘烨, 邱小玉, 等 新型降糖药达格列净的临床研究进展[J].中国医院药学杂志, 2019, 39 (18): 1896-1899.
[2] FADINI G P, LI VOLSI P,DEVANGELIO E, et al. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study [J]. J Endocrinol Invest, 2020, 43 (3): 329-346.
[3] CURE E, CURE M C. Comment on: “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment”[J]. Atherosclerosis, 2020, 296: 2-3.
[4] 陈楠, 韩睿, 张建伟, 等. 钠-葡萄糖协同转运蛋白2抑制剂的临床应用研究进展[J]. 中国糖尿病杂志, 2019, 27(4): 312-315.
[5] LUCAS RIBEIRO DOS SANTOS, RICARDO BAER FILHO. Treatment of nonalcoholic fatty liver disease with Dapagliflozin in non-diabetic patients[J]. Metabol Open, 2020,5:100028.
[6] 董松涛, 董占军. 钠-葡萄糖共转运蛋白2抑制剂作用机制及临床应用研究进展[J]. 国际药学研究杂志, 2017, 44 (9): 828-834.
[7] FADINI G P, TENTOLOURIS N, CABALLERO M I, et al. A multinational real-world study on the clinical characteristics of patients with type 2 diabetes initiating dapagliflozin in southern Europe[J]. Diabetes Ther, 2020, 11 (2): 423-436.
[8] SOKOLOV V, YAKOVLEVA T,CHU L,et al. Differentiating the SGLT1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling[J]. CPT Pharmacometrics Syst Pharmacol, 2020, 9(4):222-229.
[9] CAHN A, MOSENZON O, WIVIOTT S D, et al. Efficacy and safety of dapagliflozin in the elderly: Analysis From the DECLARE-TIMI 58 Study[J]. Diabetes Care, 2020, 43 (2): 468-475.
[10] 魏华, 殷国田. 血清可溶性ST2在新疆不同民族老年心衰患者中的改变情况分析[J]. 世界最新医学信息文摘, 2019, 19 (5): 151-152.
[11] 李莉. NT-proBNP联合血清HCY检测在心力衰竭患者治疗及预后评估中的应用[J]. 临床心血管病杂志, 2018, 34 (4): 334-337.
[12] 李培培, 段茹. 芪参归龙饮联合西药对慢性心衰合并高脂血症患者血清NT-proBNP与HE4的影响[J].中国中医基础医学杂志, 2019, 25 (7): 953-955,971. |
